IFP Advisors Inc raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Welcome back to our Sunday edition, where we round up some of our top stories and take you inside our newsroom. Jade Bonacolta landed five promotions at LinkedIn in less than seven years. The ...

The Whiting-Turner Contracting Company, one of the largest private companies in the Baltimore region, will soon relocate its headquarters for the first time in more than 50 years. It isn’t going far, ...

With Neurocrine Biosciences having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has sold the rights for its own preclinical therapy option ...

Fashion retailer Forever 21 is preparing to close at least 200 stores and lay off more than 350 employees in its corporate office as it struggles for viability. The chain has been stumbling since ...

Co-Founder and CEO of Yuno, Juan Pablo Ortega said: "Our expansion into the Middle East and the establishment of our regional headquarters in Qatar mark a pivotal step in Yuno's global growth ...

Elon Musk’s unconventional Department of Government Efficiency is certainly stirring the pot. Musk’s most recent shot across the bow came via the Office of Personnel Management. It saw DOGE ...

JPMorgan lowered the firm’s price target on Neurocrine (NBIX) to $183 from $191 and keeps an Overweight rating on the shares. The firm updated the company’s model to include Ingrezza revenue ...

Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information ...